跳至主要内容
临床试验/EUCTR2013-004249-17-GB
EUCTR2013-004249-17-GB进行中(未招募)1 期

A randomised, placebo controlled trial of extra-oesophageal reflux treatment in the management of upper respiratory symptoms. [TOPPITS: Trial of Proton Pump Inhibitors in Throat Symptoms] - Trial of Proton Pump Inhibitors in Throat Symptoms

The Newcastle upon Tyne Hospitals NHS Foundation Trust0 个研究点目标入组 332 人开始时间: 2014年2月13日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
332

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1. Referred with a persistent (over six weeks) primary throat symptom - globus, hoarseness, throat clearing, throat discomfort, choking spasms, excess mucus/postnasal drip.
  • 2. Informed consent to participate in entry screen.
  • 3. Score over 10 on the non-heartburn items of the Respiratory Symptoms Index.
  • 4. Patient has provided written informed consent for participation in the study prior to any study-specific procedures after reading the appropriate information and the required cooling off period has ensued.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range: 0
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 249
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 83

排除标准

  • Those with an RSI score excluding the lower GI item of <10.
  • Patients who are not willing to undergo flexible endoscopy could not by definition be included.
  • Inability to complete the relevant questionnaires.
  • Patients under 18 years old.
  • Endoscopic evidence of specific laryngopharyngeal pathology that would ordinarily be treated by surgical intervention or be investigated by specific investigations. This would include suspected neoplasia/dysplasia, prominent Reinke's oedema or unilateral vocal fold polyp, vocal cord palsy and rarities such as amyloid, Wegener's, sarcoid.
  • Confirmed or likely, current or prior malignancy of head and neck or oesophagus.
  • Performing voice user.
  • Pregnant or lactating woman. Woman of child bearing potential must be using adequate contraception.
  • Currently on acid suppressant, acid neutralisers and alginates and unwilling to discontinue for 4 weeks pre study washout period.
  • Prior adverse reaction to proton pump inhibitor.
  • Severe hepatic dysfunction.
  • Patients taking clopidogrel or Warfarin.
  • Patients taking Phenytoin.
  • Patients taking systemic antifungal treatment (specifically itraconazole, ketoconazole, posaconazole and voriconazole).
  • HIV positive/Patients taking Antiviral medications (atazanavir, nelfinavir, raltegravir, saquinavir, tipranavir).
  • Patients taking digoxin, cyclosporine, methotrexate, erlotinib, lapatinib, tacrolimus, sucralfate, escitalopram, fluvoxamine, St Johns wort, clozapine, Ulipristal or Cilostazol.
  • Previous participation in this study.
  • Use of other investigational study drugs within 30 days prior to study entry.

研究者

相似试验